Pfizer Global Medical Grants
LOI Deadline: January 31, 2020
The intent of this Request for Proposal (RFP) is to support preclinical, clinical and outcomes research through a competitive grant program with the intent to increase medical knowledge in the diagnosis and management of inflammatory and immune-mediated dermatologic disorders.
Pfizer is interested in supporting high quality basic science, translational, clinical and outcomes research in atopic dermatitis, alopecia areata, Phosphodiesterase 4-inhibition (PDE4), and Janus Kinase (JAK) pathways with special interest in the following topics:
- Atopic Dermatitis (AD)
- Approaches to improving adherence to pharmacologic topical therapies for atopic dermatitis
- Phenotypic differences in the clinical course and/or response to pharmacologic therapy for atopic dermatitis
- Exploring the caregiver burden in managing atopic dermatitis in children
- Exploring the cytokine profile of patients with atopic dermatitis across the age spectrum
- Phosphodiesterase 4-inhibition
- Exploring the role of PDE4 in atopic dermatitis as it relates to skin barrier function, cytokine regulation, and related symptoms and signs of inflammation, itch and pain.
- Evaluating use of a topical PDE4 inhibitor in combination or in sequence with other agents for atopic dermatitis.
- Evaluating mitigation strategies for tolerability reactions associated with pharmacologic topical agents for atopic dermatitis
- Janus Kinase Pathways
- Assessment of the role of JAK-1 dependent cytokines and the JAK/STAT pathway in the pathophysiology of atopic dermatitis or alopecia areata
- Understanding HCP treatment preferences for moderate-to-severe atopic dermatitis (i.e. MoA, RoA, possibility of drug holidays) and satisfaction with currently available therapies
- Alopecia Areata (AA)
- Exploring and defining the burden of illness of AA and associated comorbidities
- Assessment of the impact of AA in mild, moderate and severe disease on healthcare resource utilization and patient perception
- Identifying the patient/caregiver/parent perception of current therapies for alopecia areata and factors affecting switching therapies or adherence
- Developing validated scales to measure patient-related outcomes for alopecia areata
